Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANCE: radiochemotherapy with or without durvalumab for locally advanced anal carcinoma
2024-513914-36-00Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Dec 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of durvalumab in anal squamous cell carcinoma (SCCA) (2 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Disease-free survival. Started Dec 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2024-513914-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513914-36-00.